These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12438436)

  • 1. Misfolded, protease-resistant proteins in animal models and human neurodegenerative disease.
    Dickson DW
    J Clin Invest; 2002 Nov; 110(10):1403-5. PubMed ID: 12438436
    [No Abstract]   [Full Text] [Related]  

  • 2. Alpha-synuclein and neurodegenerative diseases.
    Goedert M
    Nat Rev Neurosci; 2001 Jul; 2(7):492-501. PubMed ID: 11433374
    [No Abstract]   [Full Text] [Related]  

  • 3. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies.
    Neumann M; Kahle PJ; Giasson BI; Ozmen L; Borroni E; Spooren W; Müller V; Odoy S; Fujiwara H; Hasegawa M; Iwatsubo T; Trojanowski JQ; Kretzschmar HA; Haass C
    J Clin Invest; 2002 Nov; 110(10):1429-39. PubMed ID: 12438441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases.
    Kahle PJ; Haass C; Kretzschmar HA; Neumann M
    J Neurochem; 2002 Aug; 82(3):449-57. PubMed ID: 12153470
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.
    Duda JE; Giasson BI; Mabon ME; Lee VM; Trojanowski JQ
    Ann Neurol; 2002 Aug; 52(2):205-10. PubMed ID: 12210791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
    Dev KK; Hofele K; Barbieri S; Buchman VL; van der Putten H
    Neuropharmacology; 2003 Jul; 45(1):14-44. PubMed ID: 12814657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synucleinopathies: clinical and pathological implications.
    Galvin JE; Lee VM; Trojanowski JQ
    Arch Neurol; 2001 Feb; 58(2):186-90. PubMed ID: 11176955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein degradation in Alzheimer's disease and aging of the brain.
    Tsuji T; Shimohama S
    Prog Mol Subcell Biol; 2002; 29():43-60. PubMed ID: 11908072
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathogenic effects of alpha-synuclein aggregation.
    Lundvig D; Lindersson E; Jensen PH
    Brain Res Mol Brain Res; 2005 Mar; 134(1):3-17. PubMed ID: 15790525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha synuclein in neurodegenerative disorders: murderer or accomplice?
    Mezey E; Dehejia A; Harta G; Papp MI; Polymeropoulos MH; Brownstein MJ
    Nat Med; 1998 Jul; 4(7):755-7. PubMed ID: 9662355
    [No Abstract]   [Full Text] [Related]  

  • 11. Neurodegenerative disorders with diffuse cortical Lewy bodies.
    Fleisher AS; Olichney JM
    Adv Neurol; 2005; 96():148-65. PubMed ID: 16383218
    [No Abstract]   [Full Text] [Related]  

  • 12. Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4.
    Tsuboi Y; Wszolek ZK; Graff-Radford NR; Cookson N; Dickson DW
    Neuropathol Appl Neurobiol; 2003 Oct; 29(5):503-10. PubMed ID: 14507342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
    Masliah E; Rockenstein E; Veinbergs I; Mallory M; Hashimoto M; Takeda A; Sagara Y; Sisk A; Mucke L
    Science; 2000 Feb; 287(5456):1265-9. PubMed ID: 10678833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein and transgenic mouse models.
    Fernagut PO; Chesselet MF
    Neurobiol Dis; 2004 Nov; 17(2):123-30. PubMed ID: 15474350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity.
    Klucken J; Shin Y; Masliah E; Hyman BT; McLean PJ
    J Biol Chem; 2004 Jun; 279(24):25497-502. PubMed ID: 15044495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies.
    Lindersson E; Lundvig D; Petersen C; Madsen P; Nyengaard JR; Højrup P; Moos T; Otzen D; Gai WP; Blumbergs PC; Jensen PH
    J Biol Chem; 2005 Feb; 280(7):5703-15. PubMed ID: 15590652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
    Giasson BI; Duda JE; Murray IV; Chen Q; Souza JM; Hurtig HI; Ischiropoulos H; Trojanowski JQ; Lee VM
    Science; 2000 Nov; 290(5493):985-9. PubMed ID: 11062131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons.
    Wilson CA; Murphy DD; Giasson BI; Zhang B; Trojanowski JQ; Lee VM
    J Cell Biol; 2004 May; 165(3):335-46. PubMed ID: 15123735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies.
    Hashimoto M; Masliah E
    Neurochem Res; 2003 Nov; 28(11):1743-56. PubMed ID: 14584828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.
    Uversky VN
    J Biomol Struct Dyn; 2003 Oct; 21(2):211-34. PubMed ID: 12956606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.